Global Technology Report

PCSK9 Inhibitors Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novo Nordisk, AstraZeneca, Sirnaomics, Vaxxinity, Verve Therapeutics

 Breaking News
  • No posts were found

PCSK9 Inhibitors Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novo Nordisk, AstraZeneca, Sirnaomics, Vaxxinity, Verve Therapeutics

February 28
11:25 2024
PCSK9 Inhibitors Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novo Nordisk, AstraZeneca, Sirnaomics, Vaxxinity, Verve Therapeutics
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The PCSK9 Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

PCSK9 Inhibitors Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market.

 

Some of the key takeaways from the PCSK9 Inhibitors Pipeline Report:

  • Companies across the globe are diligently working toward developing novel PCSK9 Inhibitors treatment therapies with a considerable amount of success over the years. 
  • PCSK9 Inhibitors companies working in the treatment market are Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso Biopharma, Amgen, Jiangsu Hengrui Medicine Co., Innovent Biologics, LIB Therapeutics, Ionis Pharmaceuticals, CiVi Biopharma, and others, are developing therapies for the PCSK9 Inhibitors treatment 
  • Emerging PCSK9 Inhibitors therapies in the different phases of clinical trials are- STP135G, PCSK9 inhibitor, VERVE 101, SAL-003, NNC 03850434, AZD 8233, AK102, Evolocumab, SHR-1209, Tafolecimab, LIB003 (Lerodalcibep), AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVI-008, and others are expected to have a significant impact on the PCSK9 Inhibitors market in the coming years.   
  • In December 2022, The boards of directors of Horizon Therapeutics plc and Amgen Inc. have declared their agreement to the terms of a cash offer made to the company by Pillartree Limited (“Acquirer Sub”), a recently established private limited company that is owned entirely by Amgen. The offer, which has received unanimous board recommendation, calls for Acquirer Sub to purchase all of the company’s issued and upcoming ordinary share capital.
  • In December 2022, Eli Lilly and Company declared that Akouos, Inc. was successfully acquired. With this acquisition, Lilly’s activities in the field of genetic therapies will also encompass Akouos’s portfolio of potentially ground-breaking adeno-associated viral gene therapy for inner ear disorders such sensorineural hearing loss.
  • In June 2022, Innovent Biologics, Inc. announced that the New Drug Application (NDA) for tafolecimab injection (anti-PCSK-9 antibody, R&D code: IBI306) for the treatment of primary hypercholesterolemia (including heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia) and mixed dyslipidemia had been formally accepted by the National Medical Products Administration (NMPA) of China.
  • In January 2022, A ground-breaking research collaboration and license agreement was announced by Sanofi and Exscientia to develop up to 15 novel small molecule candidates in immunology and cancer utilizing real patient samples and Exscientia’s end-to-end AI-driven platform. The companies have been working together since 2016. In 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate, which targets two distinct locations in immunology and inflammation.
  • In February 2021, A Phase III clinical study, randomized, double-blind, placebo-controlled, was started by Innovent Biologics (Suzhou) Co. Ltd. in China to assess the safety and effectiveness of IBI306 in patients with hypercholesterolemia (CREDIT-4)

 

PCSK9 Inhibitors Overview

The liver produces the protein PCSK9. Studies have indicated that individuals with elevated PCSK9 levels typically experience lifelong high cholesterol and early onset of heart disease. PCSK9 inhibitors, sometimes referred to as PCSK9i, are a novel class of medication used to reduce blood cholesterol.

 

Get a Free Sample PDF Report to know more about PCSK9 Inhibitors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight

 

Emerging PCSK9 Inhibitors Drugs Under Different Phases of Clinical Development Include:

  • STP135G: Sirnaomics
  • PCSK9 inhibitor: Vaxxinity
  • VERVE 101: Verve Therapeutics
  • SAL-003: Xinlitai Biotechnology
  • NNC 03850434: Novo Nordisk
  • AZD 8233: AstraZeneca
  • AK102: Akeso Biopharma
  • Evolocumab: Amgen
  • SHR-1209: Jiangsu Hengrui Medicine Co.
  • Tafolecimab: Innovent Biologics
  • LIB003 (Lerodalcibep): LIB Therapeutics
  • AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals
  • Cepadacursen sodium (CIVI-007): CiVi Biopharma
  • CiVI-008: CiVi Biopharma

 

PCSK9 Inhibitors Route of Administration

PCSK9 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

PCSK9 Inhibitors Molecule Type

PCSK9 Inhibitors Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

PCSK9 Inhibitors Pipeline Therapeutics Assessment

  • PCSK9 Inhibitors Assessment by Product Type
  • PCSK9 Inhibitors By Stage and Product Type
  • PCSK9 Inhibitors Assessment by Route of Administration
  • PCSK9 Inhibitors By Stage and Route of Administration
  • PCSK9 Inhibitors Assessment by Molecule Type
  • PCSK9 Inhibitors by Stage and Molecule Type

 

DelveInsight’s PCSK9 Inhibitors Report covers around 14+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further PCSK9 Inhibitors product details are provided in the report. Download the PCSK9 Inhibitors pipeline report to learn more about the emerging PCSK9 Inhibitors therapies

 

Some of the key companies in the PCSK9 Inhibitors Therapeutics Market include:

Key companies developing therapies for PCSK9 Inhibitors are –  LIB Therapeutics, AstraZeneca, CiVi Biopharma, Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Akeso Biopharma, Innovent Biologics, and others.

 

PCSK9 Inhibitors Pipeline Analysis:

The PCSK9 Inhibitors pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of PCSK9 Inhibitors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PCSK9 Inhibitors Treatment.
  • PCSK9 Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • PCSK9 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PCSK9 Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about PCSK9 Inhibitors drugs and therapies

 

PCSK9 Inhibitors Pipeline Market Drivers

  • Increasing risk of cardiovascular conditions such as myocardial infarction, coronary revascularization etc., rising healthcare expenditure globally, rising geriatric population are some of the important factors that are fueling the PCSK9 Inhibitors Market.

 

PCSK9 Inhibitors Pipeline Market Barriers

  • However, little information is available on the real impact of PCSK9 inhibitors in terms of reducing cholesterolemia, events, and the actual tolerability, use of off-label therapies and generics and other factors are creating obstacles in the PCSK9 Inhibitors Market growth.

 

Scope of PCSK9 Inhibitors Pipeline Drug Insight    

  • Coverage: Global
  • Key PCSK9 Inhibitors Companies: Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso Biopharma, Amgen, Jiangsu Hengrui Medicine Co., Innovent Biologics, LIB Therapeutics, Ionis Pharmaceuticals, CiVi Biopharma, and others
  • Key PCSK9 Inhibitors Therapies: STP135G, PCSK9 inhibitor, VERVE 101, SAL-003, NNC 03850434, AZD 8233, AK102, Evolocumab, SHR-1209, Tafolecimab, LIB003 (Lerodalcibep), AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVI-008, and others
  • PCSK9 Inhibitors Therapeutic Assessment: PCSK9 Inhibitors current marketed and PCSK9 Inhibitors emerging therapies
  • PCSK9 Inhibitors Market Dynamics: PCSK9 Inhibitors market drivers and PCSK9 Inhibitors market barriers 

 

Request for Sample PDF Report for PCSK9 Inhibitors Pipeline Assessment and clinical trials

 

Table of Contents

1. PCSK9 Inhibitors Report Introduction

2. PCSK9 Inhibitors Executive Summary

3. PCSK9 Inhibitors Overview

4. PCSK9 Inhibitors- Analytical Perspective In-depth Commercial Assessment

5. PCSK9 Inhibitors Pipeline Therapeutics

6. PCSK9 Inhibitors Late Stage Products (Phase II/III)

7. PCSK9 Inhibitors Mid Stage Products (Phase II)

8. PCSK9 Inhibitors Early Stage Products (Phase I)

9. PCSK9 Inhibitors Preclinical Stage Products

10. PCSK9 Inhibitors Therapeutics Assessment

11. PCSK9 Inhibitors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. PCSK9 Inhibitors Key Companies

14. PCSK9 Inhibitors Key Products

15. PCSK9 Inhibitors Unmet Needs

16 . PCSK9 Inhibitors Market Drivers and Barriers

17. PCSK9 Inhibitors Future Perspectives and Conclusion

18. PCSK9 Inhibitors Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories